Ignite Creation Date:
2025-12-24 @ 6:31 PM
Ignite Modification Date:
2026-03-13 @ 3:33 AM
Study NCT ID:
NCT01234857
Status:
COMPLETED
Last Update Posted:
2017-05-31
First Post:
2010-09-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2010-09-17
Start Date Type:
ACTUAL
Primary Completion Date:
2013-10-15
Primary Completion Date Type:
ACTUAL
Completion Date:
2013-10-15
Completion Date Type:
ACTUAL
First Submit Date:
2010-09-22
First Submit QC Date:
None
Study First Post Date:
2010-11-04
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-05-29
Last Update Post Date:
2017-05-31
Last Update Post Date Type:
ACTUAL